Treating a type 2 diabetic patient with impaired pancreatic islet function by personalized endoderm stem cell-derived islet tissue

著者: Jiaying Wu, Tuo Li, Meng Guo, Junsong Ji, Xiaoxi Meng, Tianlong Fu, Tengfei Nie, Tongkun Wei, Ying Zhou, Weihua Dong, Ming Zhang, Yongquan Shi, Xin Cheng, Hao Yin, Xiaoyu Mou, Yifan Feng, Xiaoliang Xu, Junfeng Dong, Duowen He, Yuanyu Zhao, Xue Zhou, Xueqi Wang, Feng Shen, Yue Wang, Guoshan Ding, Zhiren Fu - Cell Discovery 2024 被引用: 92

Type 2 diabetes (T2D) typically starts with insulin resistance in peripheral tissues and proceeds with gradual loss of islet function due to the reduction in β-cell mass or dedifferentiation of β cells 1 , 2 . More than 30% of T2D patients eventually rely on exogenous insulin treatment. Cadaveric islet transplantation is an effective treatment for insulin-dependent diabetes 3 , 4 . Notably, improved metabolic control after islet transplantation is associated with better kidney allograft function and long-term survival 5 , 6 . However, the application of islet transplantation is severely hampered due to the critical shortage of donor organs.